Relay Therapeutics is trading 4.1% up today at $20.17 as investors continue to digest positive clinical data and subsequent analyst upgrades.
- The rally follows strong Phase 2 ReInspire results for zovegalisib in vascular anomalies and promising interim breast cancer data for RLY-2608.
- Bullish analyst notes and price target hikes earlier this week have fueled company-specific optimism.
- Shares are outperforming the broader market despite general weakness in the biotech and tech sectors.